WORLD HEALTH ORGANIZATION
India Launches First Indigenous Dengue Vaccine Phase 3 Trial with Over 10,000 Participants
The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated India's first Phase 3 clinical trial for an indigenous tetravalent dengue vaccine called DengiAll.
Bharat Biotech and GSK Pledge to Cut Malaria Vaccine Price by More Than Half to Under $5 by 2028
Bharat Biotech and GSK announced they will reduce the price of the world's first malaria vaccine RTS,S by more than half to less than $5 per dose by 2028.
Trinity Biotech Receives WHO Approval for Offshore Manufacturing of HIV Rapid Test
Trinity Biotech received World Health Organization approval for offshored and outsourced upstream manufacturing of its TrinScreen HIV rapid test, marking a critical milestone in the company's transformation plan.
Favipiravir Shows Promise Against Deadly Chandipura Virus in Preclinical Studies
The antiviral drug Favipiravir demonstrated substantial protection against Chandipura virus in preclinical studies conducted by India's National Institute of Virology.
CanSinoBIO Launches iPneucia® 13-Valent Pneumococcal Vaccine Optimized for Chinese Children
CanSino Biologics has launched iPneucia®, a 13-valent pneumococcal conjugate vaccine specifically optimized for China's local pneumococcal epidemiology to protect Chinese children.
Nature Study Validates Non-Invasive Fat Reduction Technology for Abdominal Obesity Treatment
A peer-reviewed study published in Nature Scientific Reports demonstrates statistically significant abdominal fat reduction using Alma's Accent Prime ultrasound and radiofrequency technology in Korean women with abdominal obesity.
GeoVax Receives EMA Approval to Skip Phase 1/2 Trials for Mpox Vaccine, Accelerating Path to Market
GeoVax Labs received positive Scientific Advice from the European Medicines Agency for GEO-MVA, a Modified Vaccinia Ankara-based vaccine targeting Mpox and smallpox prevention.
Intravenous Rehydration Shows Safety in Severely Malnourished Children, Challenging WHO Guidelines
A randomized controlled trial involving 292 children across four African countries found that intravenous rehydration was as safe as oral rehydration for children with severe acute malnutrition and gastroenteritis.
WHO's mRNA Technology Transfer Programme Enters Phase 2.0, Targeting Commercial-Scale Production in Low- and Middle-Income Countries
The WHO and Medicines Patent Pool's mRNA Technology Transfer Programme is transitioning to Phase 2.0 (2026-2030), moving from proof of concept to commercially sustainable manufacturing in 15 partner countries across Latin America, Africa, Eastern Europe and Asia.
Valneva's Chikungunya Vaccine Shows Sustained Antibody Response in Children After Six Months
Valneva's single-shot chikungunya vaccine IXCHIQ demonstrated robust antibody persistence and safety in children aged 1-11 years at six months post-vaccination, with a 96.5% seroresponse rate in infection-naïve children receiving the full dose.